Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
ICo Therapeutics Inc: Conference & Catalyst
read article here-http://seekingalpha.com/instablog/6156631-kyles-picks/2810363-ico-therapeutics-inc-conference-and-catalyst
Did not mean to post that many times, ipads acting up
Link here for abstract march 25th http://firstglancebioinvestor.blogspot.com
Link here for abstract march 25th http://firstglancebioinvestor.blogspot.com
Interesting conference for ONCS coming up in June
http://clinicalkyle.blogspot.com/
May 21-24, 2014 ASGCT 17th Annual Meeting
Scientific Symposium 213
Thursday May 22, 2014
Richard Heller, PHD
Non-Viral Gene Transfer of pIL-12 for the Treatment of Melanoma: Results from Phase 1 and 2 Trials
http://clinicalkyle.blogspot.com/
D.D. for the next few qtr's 2013-2014
1)7th Vaccine & ISV Congress Sitges, Barcelon Spain 27-29 October 2013
Monday 28 October, 15:30-17:30
*Immunoadjuvant IL-33 enhances Human Papillomavirus 16 E6/E7-specific cell-mediated immunity and induced potent antitumor immunity
University of Pennsylvania, USA, 2Inovio Pharmaceuticals, Inc, USA
*Induction of potent CTL activity for cancer immunotherapy: Development of VGX-3100 for HPV associated cancers and hTERT DNA vaccine for solid tumors
J. Yan1, M.P. Morrow1, P. Pankhong2, T. Shin2, N. Obeng-Adjei2, J.N. Walters2, A.S. Khan1, M. Bagarazzi1, D.B. Weiner2, N.Y. Sardesai*1
1Inovio Pharmaceuticals, Inc., USA, 2University of Pennsylvnia, USA
*HIV-1 Env DNA Vaccine Plus Protein Boost Delivered By EP Expands B- And T-Cell Responses And Neutralizing Phenotype in vivo (poster)
K. Muthumani1, K. Broderick2, N. Hutnick1, M. Wise1, J. Yan2, J. Mendoza2, C. Tingey1, S. Flingai1, N. Sardesai2, D. Weiner*1
1University of Pennsylvania School of Medicine, USA, 2Inovio Pharmaceuticals Inc, USA
*Synthetic enhanced EP delivered Ig DNA vector drives biologically relevant Anti-HIV-1 envelope responses in Vivo
K. Muthumani1, S. Flingai1, M. Wise1, C. Tingey1, E. Reuschel1, K. Ugen2, D. Weiner*1
1Department of Pathology and Laboratory Medicine, USA, 2University of South Florida Morsani College of Medicine, USA
*The co-delivery of esx multivalent TB DNA vaccines with electroporation induces potent immune responses
(poster)
D.O. Villarreal*, D.B. Weiner
University of Pennsylvania, USA
2)Pennvax GP trial(launch coming before years expected pr in a few weeks)
3)DNA-based Influenza Vaccine in the Elderly
ClinicalTrials gov Identifier: (NCT01587131)
Secondary Outcome Measures:
Estimated Enrollment: 50
Study Start Date: June 2012
Estimated Study Completion Date:October 2013
Estimated Primary Completion Date: July 2013 (Final data collection date for primary outcome measure)
4)Mid November..expected update on institutional buying(discussions currently in progress)
5)NOV 25, 2013 Brean Capital Life Science Summit
New York, NY
6)Leukemia CML & AML Additional phase II data (2013
7) Biodefense projects dates are never listed but new work has been completes on the Lassa Virus and Puumala & Hantaan viruses as as recent as last month update should be coming before years end on one of the projects
8)DEC 3-4, 2013
Piper Jaffray Healthcare Conference
New York, NY
9)DEC 3-5, 2013
LD Micro Conference
Los Angeles, CA
10)PENNVAX-G DNA Vaccine
Estimated Enrollment: 92
Study Start Date: February 2010
Estimated Primary Completion Date:December 2013 (Final data collection date for primary outcome measure)
11) Malaria vaccine funded by path/mvi 1st qtr 2014 P1 trial launch
12)Cell & Gene Therapy Forum 2014, 27th–29th January
Cancer vaccines: Learning from past successes and failures to deliver
game-changing efficacy
2.30 Chair’s introduction
Dr Mark Bagarazzi, Chief Medical Officer, Inovio
Industry case studies
Latest clinical data from leading cancer vaccines in development
What progress is being made in developing a viable business model for autologous cancer
vaccines?
What have we learnt in terms of improving the potency of cancer vaccines?
13)6th Immunotherapeutics & Immunomonitoring (Jan 29, 2014 to Jan 31, 2014 San Diego, CA, USA)
10:55 DNA Delivery to Skin and Muscle is Enhanced by Next Generation Electroporation Devices and has Generated Clinically Relevant Immune Responses
Kate Broderick
Director, Research & Development
Inovio
The magnitude of the immune response to a DNA vaccine depends on three criteria - optimized vector design, optimized vaccine formulations with or without suitable molecular adjuvants and the successful delivery and subsequent expression of the DNA plasmid in the target tissue. In vivo electroporation (EP) is an efficient non-viral method for enhancing DNA vaccine delivery and immunogenicity.
Here, we discuss the use of EP in both animal models and human in the clinic and describe novel concepts for DNA delivery to target tissues such as the skin and muscle. We outline the combination of DNA vaccine and EP delivery to target both therapeutic and prophylactic diseases in both the infectious disease and oncological arenas.
VGX-3100 was developed as a two plasmid combination vaccine targeting the E6/E7 gene products of HPV-16 and 18 as an immune therapy for cervical dysplasia. Vaccination of humans with highly optimized HPV constructs delivered by CELLECTRA® EP device induces significant levels of both cellular and humoral responses.
DNA plasmids combined with EP device modalities may have important clinical applications for delivery of prophylactic and therapeutic vaccines against diseases such as HIV, malaria and tuberculosis that require both cellular and humoral immune responses for protection and elimination since this device offers a safe, tolerable and most importantly, potent method to administer DNA vaccines.
Day 1 - Thursday, January 30, 2014
14)VGX-3100 SynCon® vaccine for cervical dysplasia/cancer CIN 2/3
Phase II study enrollment completed; top-line data expected in mid-2014.
15)INO-5150 SynCon® immunotherapy for prostate cancer
phase I/IIa 1H 2014 (Roche Milestone payment also)
Many other projects are being launched 2014 including Breast/lung cancer INO-1400 hTERT,and hep B. Dr. Kim recently stated at the last conference investors can expect a few surprises before years end 2013. Pennvax B therapeutic update is expected soon by investors, but no guidance has been giving by management on that yet so we cant confirm a time frame.
A week where Providence became a hub of scientific discovery and commercialization
By Richard Asinof
PROVIDENCE – The seventh annual Vaccine Renaissance Conference brought together many of the nation’s leading scientific experts on vaccine research on Oct. 16-18. The conference, hosted by iCubed, the Institute for Immunology and Informatics at the University of Rhode Island, was a scientific gathering grounded in the culture of collaboration and the serious exchange of ideas.
As the introduction to the conference urged attendees: “Please take every opportunity to ask questions, interact with each other, and share your work. We hope that you will succeed in creating new networks of collaboration.”
The topics addressed at the opening session on Thursday morning, Oct. 17, captured the breadth of scientific expertise. Dr. Phillip K. Russell, founding president of The Albert B. Sabin Vaccine Institute, and a retired Major General who served in the in the U.S. Army Medical Corps for three decades, gave a 30-minute talk criticizing the current lack of preparedness by the U.S. government to develop countermeasures against bioterrorism.
It was the same message that Russell had delivered six days earlier in testimony before the House Armed Services Committee Subcommittee on Intelligence, Emerging Threats and Capabilities, when he said: “The threat that a biologic attack by terrorists or other adversaries poses to our armed forces or our nation is not fully understood or recognized by the leadership of our defense programs. Second[ly], the countermeasure development programs of the Department of Defense essential to protecting our armed forces and our nation have a long, very well-documented record of failure and will continue to fail if not corrective actions are taken.”
As Russell told ConvergenceRI before his talk, the reasons why the programs are not performing include: the difficulty of the science, the cumbersome contracting methods, the lack of good leadership at the White House, and the failure to embrace new technology to enhance biodefense medical counter measures.
The importance of the conference, he continued, “is that vaccines on demand are creating an opportunity to change the strategies moving forward/ One hopes that the funding agencies will recognize the value of the advancing technologies and put them into the program so that we can enhance our capabilities.”
Russell said that the reason he was attending the conference was because it provided an opportunity “to learn what the new vaccine science and technologies offer to develop the countermeasures that we need.”
Russell was followed by Alan Barrett, director of the Study for Vaccine Development at the University of Texas Medical Branch, who discussed in a rapid-fire presentation the genomic analysis comparing the live attenuated yellow fever vaccine 17D-204 to its virulent parental strain Asibi by deep sequencing.
In turn, Barrett was followed to the podium by Kate Broderick, director of R&D at Inovio, one of the sponsors of the conference, who described her company’s explorations of targeting dermal tissue to deliver DNA biologics and vaccines.
At the end of each session, participants, almost all of whom had laptops and mobile devices to capture details, engaged in a question-and-answer dialogue that probed the scientific design of the work begin done.
A new, better, more efficient flu vaccine
Manon M.J. Cox, president and CEO of Protein Sciences Corporation in Meriden, Conn. Her company has developed an FDA-approved influenza vaccine manufacturing process using the company’s proprietary protein expression technology that can produce high quality recombinant proteins, quickly, reliably and at a low cost.
Cox, who is originally from the Netherlands, has been a regular participant at the Vaccine Renaissance Conference. This year, her company is a sponsor, and she has brought with her a number of the company’s top scientists, she told ConvergenceRI, because “it’s important to have these meetings where scientists have an opportunity to share ideas by talking with one another so we can come up with better solutions.” And, she continued, “I brought a couple of scientists with me because I think it’s important for them to participate.”
Cox praised the work of iCubed as a very exciting institute and the efforts of Dr. Anne S. De Groot, CEO of EpiVax, Inc., and director of iCubed.
Noting that Rhode Island was a small state sandwiched by Boston on one side, with its ability to attract a lot of scientists and pay relatively high salaries, and by New York on the other side, Cox saw the potential of developing a New England consortium between Rhode Island and Connecticut. “This little conference here may be very important to that,” she said. “It’s right in the middle, very close to Boston, close to Connecticut, we need to expand that reach to get New York involved. We might be able to make things happen.”
Cox described her company’s work in developing an FDA-approved flu vaccine using recombinant proteins with a certain level of frustration.
“This concept was known for the last 40 years. For the last 30 years we have had the technology to make the vaccines. And it took 20 years to convince the FDA that this vaccine was safe and effective,” she said.
At the same time, Cox continued, 95 percent of the influenza virus vaccines are still grown using a 60-year-old technology, using chicken eggs.
Today, there are still only three FDA-approved recombinant vaccines, according to Cox.
The Hepatitis B vaccine, which will ultimately prevent liver cancers, costs about $400 a dose.
The second is the human papillomavirus, or HPV vaccine, associated with the prevention of cervical cancer, that Cox said was still a very expensive vaccine, costing about $300 a dose.
The third is her company’s influenza vaccine.
“People are used to getting the flu vaccines for $10 or $20. When we came out with our product and we priced it at $32, there was resistance,” Cox said. “As we are scaling up our production, we hope to bring that price down dramatically. My personal goal is to have nations that can afford to pay a little more for vaccines pay that amount, so the vaccine will be available in developing countries.”
Commercialization of technology
Two days before, just three blocks away, another important conference was held in Providence, a Rhode Island health care showcase hosted by Brown University’s Technology Ventures Office.
The goal of the showcase was to “accelerate commercialization and innovation, align regional health care expertise and strengthen the translational bridge that will bring research and discovery to the marketplace.”
The showcase also sought to “heighten awareness” of Rhode Island’s Knowledge District.
An overflow crowd of more than 300 people attended at various times over the seven-hour event at the Warren Alpert Medical School, which featured three panel discussions focused on future health challenges: aging populations and aging brains, the future of genomics in medicine, and treatment of disease using nutritional strategies.
Gov. Lincoln D. Chafee welcomed the gathering, followed by Brown University Provost Dr. Mark Schlissel.
The keynote speaker was John L. Brooks III, president and CEO of the Joslin Diabetes Center in Boston, who has founded four different life sciences companies. Brook discussed the disruptive forces at play in the health care sector.
“The days that you see your doctor four times a year are over,” Brooks predicted, saying that the use of health IT, the development of virtual apps and portals will change the dynamics of how patients are “treated” in the future.
Among the attendees was: Douglas E. Denninger, an intellectual property lawyer who specializes in patents, trademarks and copyrights; Barbara R. Schoenfeld, director, and Kevin Centrofanti, senior managing director, at the investment banking firm of Brooks, Houghton & Company, Inc., in New York City; Kenneth Levy, senior vice president of Special Projects at Johnson & Wales University; Richard G. Horan of the Slater Technology Fund; Virginia M. Burke, president and CEO of the Rhode Island Health Care Association; Erik Wernevi, founder and president of the Nordic Technology Group, a startup firm in developing new technology in the aging population sector; and Stephen Lane, co-founder, chairman and chief venture office of Ximedica, who moderated the panel discussion on medical nutrition.
In advance of the panel discussions, some of the participants met in pre-wired meetings to discuss commercialization opportunities, coordinated by Katie Gordon of the Brown Technology Ventures program.
Unlike the Vaccine Renaissance Conference, the health care showcase had a sense of experts talking at, not with, the participants, and dialogue was often limited to a few questions at the end of each session,
That was the week that was
Between the health care showcase on Oct. 15, the Vaccine Renaissance conference from Oct. 16-18, and the Startup Weekend Providence, hosted by BetaSpring, from Oct. 18-20, Rhode Island’s innovation ecosystem was fully engaged in high-yield conversations.
What appeared to be missing, however, was a sense of connection and convergence between the three important events – as well as news coverage of the two major conferences – except here in ConvergenceRI.
7th Vaccine & ISV Congress Sitges, Barcelon Spain
27-29 October 2013
Premier conference on vaccines and vaccination. The 7th Vaccine & ISV Congress will feature science and public health topics, from primary vaccine research and vaccine manufacturers, to governmental policy, safety and regulation. The Vaccine & ISV Congress has enjoyed an exciting history covering all aspects of vaccines since 2007. Over this time a wealth of knowledge has been presented, including talks from eminent scientists such as Stanley A. Plotkin, Rino Rappuoli, Ab Osterhaus, Walter A. Orenstein, Myron M. Levine, Adel Mahmoud and Gregory A. Poland
http://www.vaccinecongress.com/
Monday 28 October, 15:30-17:30
*Immunoadjuvant IL-33 enhances Human Papillomavirus 16 E6/E7-specific cell-mediated immunity and induced potent antitumor immunity
University of Pennsylvania, USA, 2Inovio Pharmaceuticals, Inc, USA
*Induction of potent CTL activity for cancer immunotherapy: Development of VGX-3100 for HPV associated cancers and hTERT DNA vaccine for solid tumors
J. Yan1, M.P. Morrow1, P. Pankhong2, T. Shin2, N. Obeng-Adjei2, J.N. Walters2, A.S. Khan1, M. Bagarazzi1, D.B. Weiner2, N.Y. Sardesai*1
1Inovio Pharmaceuticals, Inc., USA, 2University of Pennsylvnia, USA
HIV-1 Env DNA Vaccine Plus Protein Boost Delivered By EP Expands B- And T-Cell Responses And Neutralizing Phenotype in vivo (poster)
K. Muthumani1, K. Broderick2, N. Hutnick1, M. Wise1, J. Yan2, J. Mendoza2, C. Tingey1, S. Flingai1, N. Sardesai2, D. Weiner*1
1University of Pennsylvania School of Medicine, USA, 2Inovio Pharmaceuticals Inc, USA
Synthetic enhanced EP delivered Ig DNA vector drives biologically relevant Anti-HIV-1 envelope responses in Vivo
K. Muthumani1, S. Flingai1, M. Wise1, C. Tingey1, E. Reuschel1, K. Ugen2, D. Weiner*1
1Department of Pathology and Laboratory Medicine, USA, 2University of South Florida Morsani College of Medicine, USA
The co-delivery of esx multivalent TB DNA vaccines with electroporation induces potent immune responses
(poster)
D.O. Villarreal*, D.B. Weiner
University of Pennsylvania, USA
Inovio will be well represented at this conference
once a company has established potential as ino has..and their cash runway is maintainable to see some progress made..you found yourself a good investment..an investment is a risk as we all know,so i try to minimize those through research,contacts and lots of reading
no problem, i agree the more reading done on the sector as a whole helps gauge outlook, market activity and general interest in the companies and products we as investors choose to park our money in
Full transcript from town hall mtg (new)
http://www.townhall-la.org/sites/default/files/DrJJosephKim092413Transcript.pdf
BIO Investor Forum October 8-9, 2013
Therapeutic Workshops
The Ultimate Rejection: Fighting Cancer with Immunotherapy
Tuesday, October 8, 2013, 10:30 a.m. - 11:25 a.m., Twin Peaks North/South
Enhancing the human body’s natural immune system to stimulate response and produce effective treatments has long been thought to be a promising a approach to fighting cancer and other debilitating illnesses. By leveraging the body’s own ability to fight disease, immunotherapeutics effectively “work smarter” than traditional treatments. With pharma companies wiling to pay top dollars to develop these drugs, the field of cancer immunotherapy has piqued the interest of investors as well. This year’s ASCO spotlighted lung cancer as the newest target for immunotherapy. Hear experts from companies at the forefront of this exciting field discuss what lies ahead.
Moderator
Joseph Pantginis, PhD, Senior Research Analyst, ROTH Capital Partners
Panelists
James B. Breitmeyer, MD, PhD, Division President Cancer Vaccines, Executive Vice President, Bavarian Nordic A/S
Lawrence Fong, MD, Associate Professor, Department of Medicine (Hematology/Oncology), UCSF Medical Center
Paul G. Higham CEO immatics biotechnologies GmbH
J. Joseph Kim, PhD, President, CEO & Director, Inovio Pharmaceuticals
http://www.bio.org/events/conferences/participating-investors
send me link to full text please
nice thank you for finding that info i wonder what companies these scientist work for i know it says scrpits but if we look deeper i wonder what we will find
i read that abstract interesting stuff..some ino studies are listed under the references but i cant confirm if ino's ep device was tested in this study it does say electroporation was used but doesnt say what device..it would be nice to confirm if ino was involved, either way the abstract is validation of inos methods and a lot of the language in the abstract was simillar to the abstracts with ino & novartis
agreed the delivery tech and recent advancements on the optimizing of the plasma give ino a solid platform..not to mention after years of refining this INO scientist are the go to people on ep and dna vaccines which are being studied by big pharma and government
(NEW)Optimized and enhanced DNA plasmid vector based in vivo construction of a neutralizing anti-HIV-1 envelope glycoprotein Fab
Kar Muthumani*, Seleeke Flingai, Megan Wise, Colleen Tingey, Kenneth E Ugen, David B Weiner
Kar Muthumani
*Corresponding author
Department of Pathology and Laboratory Medicine; University of Pennsylvania School of Medicine; Philadelphia, PA USA
Seleeke Flingai
Department of Pathology and Laboratory Medicine; University of Pennsylvania School of Medicine; Philadelphia, PA USA
Megan Wise
Department of Pathology and Laboratory Medicine; University of Pennsylvania School of Medicine
Colleen Tingey
Department of Pathology and Laboratory Medicine; University of Pennsylvania School of Medicine; Philadelphia, PA USA
Kenneth E Ugen
Department of Molecular Medicine; University of South Florida
Morsani College of Medicine; Tampa, FL USA; Center for Molecular Delivery; University of South; Tampa, FL USA
David B Weiner
Department of Pathology and Laboratory Medicine; University of Pennsylvania School of Medicine; Philadelphia, PA USA
Abstract
Monoclonal antibody preparations have demonstrated considerable clinical utility for the treatment of specific malignancies, as well as inflammatory and infectious diseases. Antibodies are conventionally delivered by passive administration, typically requiring costly large-scale laboratory development and production. Additional limitations include the necessity for repeat administrations, and the length of in vivo potency. Therefore, the development of methods to generate therapeutic antibodies and antibody like molecules in vivo, distinct from an active antigen-based immunization strategy, would have considerable clinical utility. In fact, adeno-associated viral (AAV) vector mediated delivery of immunoglobulin genes with subsequent generation of functional antibodies have recently been developed. As well, non-viral vector mediated nucleic acid based delivery technology could permit the generation of therapeutic/prophylactic antibodies in vivo, obviating potential safety issues associated with viral vectors. This delivery strategy has limitations as well, mainly due to very low in vivo production. In this report we have constructed an “enhanced and optimized” DNA plasmid technology to generate immunoglobulin heavy and light chains (i.e., Fab fragments) of an established neutralizing anti-HIV envelope glycoprotein monoclonal antibody (VRC01). The “enhanced” DNA (E-DNA) plasmid technology includes codon/RNA optimization, leader sequence utilization, as well as targeted potentiation of delivery and expression of the Fab immunoglobulin genes through use of adaptive in vivo electroporation. The results demonstrate that delivery by this method of a single administration of the optimized Fab expressing constructs resulted in generation of Fab molecules in mouse sera possessing high antigen binding and HIV neutralization activity for at least 7 d against diverse HIV isolates. Importantly, this delivery strategy resulted in a rapid increase (i.e., in as little as 48 h) in Fab levels when compared with protein-based immunization. The active generation of functional Fab molecules in vivo has important conceptual and practical advantages over conventional ex vivo generation, purification and passive delivery of biologically active antibodies. Further study of this technique for the rapid generation and delivery of immunoglobulin and immunoglobulin like molecules is highly relevant and timely.
https://www.landesbioscience.com/journals/vaccines/article/26498/
Dose-sparing and intradermal applications
New approaches to bridging the gap
http://sites.path.org/vpdt/dose-sparing-and-intradermal-applications/
DNA Vaccines Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 -
- Description-
Vaccines have been in use since decades to provide immunological responses against diseases. A conventional vaccine is a biological preparation of weakened or attenuated, killed forms of a microbe or one of its cellular components, while a DNA vaccine is composed of genetically engineered DNA. When a DNA vaccine is injected into the cells of an organism, it stimulates organism’s immune system to produce immunity against the encoded antigens. DNA vaccines have a number of advantages over conventional vaccines such as when a conventional vaccine is administered, it activates only antibody reaction while a DNA vaccine activates antibody as well as cell mediated reaction. This new generation vaccine also offers fewer side effects compared to conventional vaccines.
The market for DNA vaccines is segmented into human DNA vaccines and animals DNA vaccines market. Currently there are no approved DNA vaccines for human but more than 100 products are under clinical trial for a variety of diseases including HIV infection, cancer and infectious diseases. Pennsylvania based Inovio Pharmaceuticals has it’s Syncon brand of vaccines in clinical trial for a variety of cancers and infectious diseases. On the other hand there are three DNA vaccines approved for animal health. The first vaccine was approved in the year 2005 for use in horses against West Nile Virus. Some of the pipeline DNA vaccines developed by Vical are Apex IHN for infectious hematopoietic necrosis virus and ONCEPT for melanoma in dogs.
The global market for DNA vaccines is growing impressively under the influence of advantages associated with this new generation of vaccines such as fewer side effects, ease of development and lower cost and continued development in biotechnology arena. The human health segment is expected to grow at relatively higher CAGR compared to animal health segment. Some of the notable companies operating in this market are Novartis Animal Health, Inovio Biomedical Corp, Merck & Co., Dendreon Corporation, Astellas Pharma, Vical, Sanofi and Tekmira Pharmaceuticals.
http://www.transparencymarketresearch.com/dna-vaccines-market.html#sthash.vCHlx05I.dpu
JOIN THE CONVERSATION WITH DR. J. JOSEPH KIM
September 24 @ 11:30 am - 1:30 pm
DR. J. JOSEPH KIM, PRESIDENT & CEO OF INOVIO PHARMACEUTICALS
ARE WE PREPARED FOR THE NEXT PANDEMIC FLU VIRUS? IS A NEW UNIVERSAL VACCINE THE ANSWER?
Tuesday, September 24, 2013
11:3am – REGISTRATION
12pm – Lunch
12:30pm – 1:30pm – Program
Millennium BILTMORE HOTEL
506 S. Grand Avenue
Los Angeles, CA 90071
$55 – Members
$75 – Non Members
To REGISTER, https://www.townhall--la.org/civicrm/event/info?reset=1&id=1007
or Call 213-628-8141
DR KIM J JOSEPH – SEPT 24
http://laedc.org/event-page/join-the-conversation-with-dr-j-joseph-kim/
half true your correct any one can submit an article for publication..guess what they've told the last few that have(minus amit)
http://www.ripoffreport.com/r/Amit-Ghate-Seeking-Alpha/Select-StateProvince/Amit-Ghate-Seeking-Alpha-Amit-Ghate-aka-a-writter-heavily-backed-by-seeking-alphainvest-1083428
looks like someone finally had enough of amits manipulation
Is Inovio undervalued ?
yes 420 mill deal Roche priced in on cellectra ep use,prostate cancer and heb b(pre clinical vaccines)
Ino's market cap right now is approx 480mill
so lets look at what wallstreet hasn't priced in yet
1-Phase II vgx 3100 Cervical dysplasia-?
2-Pennvax universal HIV vaccine-?
3-Universal Flu vaccine-?
4-INO-8000 hep c-?
5-Malaria vaccine-?
6-Universal cancer vaccine-breast,lung-?
7-Leukaemia
8-Ebola & Marburg filoviruses, foot-and-mouth disease,lasa virus
years of upside coming ino's way
Vaccine Market research report evaluates the global vaccine market by technology class, types, end users, disease indication, and geography.
(PRWEB) August 20, 2013
The "Vaccine Market - By Technology & Types, Trend Analysis By Various Classes – Live / Attenuated, Subunit, Toxoid, Conjugate, DNA, Recombinant Vector, Synthetic, Dentritic Vaccines And By Indications – Infectious Diseases, Cancer, Allergy, Diabetes, Cardiovascular Disease With Market Landscape Analysis - Global Forecasts To 2022 " analyzes and studies the major market drivers, restraints, and opportunities in North America, Europe, Asia, and the Rest of the World.
This report studies the global vaccine market, with forecast to 2022.
Within the healthcare industry, the vaccine market was initially considered a low-profit venture but is currently perceived with renewed interest among industry circles due to its high demand with respect to emerging infectious diseases. Furthermore, an improved understanding of the immune system has paved new opportunities for developing novel preventive and therapeutic vaccines.
This market research report evaluates the global vaccine market by technology class, types, end users, disease indication, and geography. Furthermore, the technology class is divided into eight segments, namely, live/attenuated, toxoid, conjugate, sub-unit, recombinant vector, DNA, synthetic, and dentritic vaccines. Of the above mentioned segments, sub-unit vaccine is the largest revenue segment; however, synthetic vaccines, recombinant vector vaccines, and DNA vaccines will be the fastest-growing segments.
The global vaccine market was valued at $27 billion in the year 2012. At the end of 2013, the market is expected to be $32.05 billion and is poised to reach approximately $84 billion by 2022, growing at a CAGR of 11.36% from 2013 to 2022.
Therapeutic vaccines, specifically targeting cancers and allergies, will offer vast opportunities for new players entering this market. The launch of the first FDA-approved therapeutic vaccine, Provenge by Dendreon (U.S.), for treating prostate cancer has acknowledged the potential of vaccines in therapeutics. This scenario is expected to further revolutionize the industry towards massive growth in the next 5 to 10 years.
The global market for vaccines is expected to grow, backed by technological advancements with respect to the development of novel vaccines towards emerging infectious diseases, cancers, and allergies. The market will experience continuous improvements in vaccine design, delivery methodologies, and manufacturing in large-scale process. The market is witnessing a trend towards development of personalized vaccines. Additionally, the demand for safe and cost-effective drugs for the treatment of many cancers and HIV infection, which could be addressed by therapeutic vaccines, will remarkably fuel market growth.
North America is the largest hub for the vaccine market, accounting for the largest share, followed by Europe and Asia. North America and Europe are expected to grow at a steady pace. However, the Asia-Pacific market, particularly India and China, is expected to witness a boost in demand and is poised to register maximum growth over the next 10 years, owing to the increase in aging population and prevalence of various infectious diseases.
The key players in this market are Novartis (Switzerland), Glaxo Smithkline (U.K.), Merck (U.S.), Sanofi (France), Pfizer (U.S.), Antigen Express, Inc. (U.S.), Aduro Biotech (U.S.), Genticel (France), Biondvax (Israel), Immune Targeting Systems (U.K.), Prokarium (U.K.), Immunobiology Ltd. (U.K.), Liquidia Technologies (U.S.), Alphavax (U.S.), and Bavarian Nordic (Denmark).
http://www.sfgate.com/business/press-releases/article/Vaccine-Market-to-Reach-84-44-Billion-by-2022-at-4746616.php
IMVACS conference THURSDAY, August 15
Novel Vaccines: Innovations & Adjuvants
2:00 Skin Delivery of Flu Vaccine with Micro Arrays
Derek O'HaganDerek O'Hagan, Ph.D., Global Head, Vaccine Delivery Research, Novartis Vaccines
The coming years will see the introduction of a range of new vaccines against important infectious diseases. It will prove a challenge to incorporate these vaccines into the already crowded schedules for infant immunization. Moreover, many of these vaccines will be targeted at different population groups who may not normally accept regular vaccines, including adolescents and the elderly. It would be preferable for patient compliance if these vaccines could be administered without the use of conventional needles. Although novel rotes of vaccine delivery have been of long term interest, so far there has been limited commercial success. Nevertheless, progress has been made recently on skin delivery in particular. This presentation will review some of the technology concepts under current investigation, including skin delivery technologies.
Geoffrey O. Ouma...SVM scientific session June 13-15, 2013
Young inVeStigator
aWard finaliStS
basic Science—angiogenesis/Vasculogenesis
Yia 1 In Vivo electroporation of
Constitutively expressed Hif-1 Plasmid dna
enhances neovascularization in a Mouse
Model of Hindlimb ischemia
Background: Hypoxia-inducible factor-
1alpha (HIF-1a) is a transcription factor that stimulates
angiogenesis during tissue ischemia. Electroporation
(EP) enhances tissue DNA transfer. We evaluated the
neovascularization efficacy of EP of a constitutively
expressed HIF-1a DNA compared to intramuscular (IM)
injection in a mouse model of limb ischemia.
Methods: Mice with ligated left femoral artery were
assigned to one of the three groups: (1) HIF-EP (n=13,
EP of 20 µl HIF-1a plasmid DNA); (2) HIF-IM (n=14, IM
injection of 20 µl HIF-1a plasmid DNA); (3) pVAX-EP
(n=12, EP of 20 µl empty plasmid DNA). Limb perfusion
recovery by Laser Doppler Perfusion Imager, limb function
and limb necrosis were measured. Muscle tissues were
stained for necrosis (H&E); capillary density (anti-CD31);
and collateral vessels and size (anti-a-SMA).
Results: EP of HIF-1a DNA significantly boosted limb
perfusion (HIF-EP: 41.03 ± 0.15 vs. HIF-IM: 0.78 ± 0.064;
P < .05, vs. pVAX-EP: 0.41 ± 0.019; P < .001), limb
function recovery (HIF-EP: 3.5 ± 0.58 vs. HIF-IM, 2.4 ±
1.14; p < 0.05, vs. pVAX-EP: 2.4 ± 1.14; P < .001), and
reduced limb auto-amputation (HIF-EP: 77% ± 12% vs.
HIF-IM: 43% ± 14%; P <.05 vs. pVAX-EP: 17% ± 11%; P
< .01). Muscle necrosis declined (HIF-EP: 20.7% ± 1.75%
vs. HIF-IM: 44% ± 3.73; P < .001, vs. pVAX-EP: 60.05%
± 2.17%; P < .0001), capillary growth improved (HIFEP: 96.83 ± 5.72 vessels/hpf vs. HIF-IM: 62.87 ± 2.0
vessels/hpf; P < .001, vs. pVAX-EP: 39.37 ± 2.76 vessels/
hpf; P < .0001), collateral vessels increased (HI-EP: 76.33
± 1.94 vessels/hpf vs. HIF-IM: 37.5 ± 1.56 vessels/hpf;
P < .0001, vs. pVAX-EP: 18.5 ± 1.34 vessels/hpf; P <
.00001), and the collaterals were larger (HIF-EP: 15,521.67
± 1,298.16 µm² vs. HIF-IM: 7,788.87 ± 392.04 µm²; P <
.001 vs. pVAX-EP: 4,640.25 ± 614.01 µm²; P < .0001).
Conclusions: In vivo EP-mediated delivery of HIF-1a DNA
is more effective in enhancing neovascularization than
IM injection in a mouse model of limb ischemia. This
modality warrants further studies in the treatment of
critical limb ischemia.
http://www.vascularmed.org/annual_meeting/2013-SVM-Meeting-Program.pdf
justabroker i do check the Korea VGX site once in awhile but haven't this week thank you for sharing that i had no idea
the lease info should be in the 10q, Inovio's new office is in San Deigo, the thing about San Diego is almost every US Pharma company has a presence there..they call SD the biotech capitol of the world
No I won't be attending, I'm out here in LA I hope to make it over to New York sometime in the next year I've been planning on it, Next time INO has a conference in LA or San Diego I'm going to try to make it.
thanks Pat just trying to pass along some interesting info
Jeffrey Ulmer is Head of External Research for Novartis Vaccines
-2008-
"There are a lot of potential pitfalls along the way of getting the DNA from a syringe into a cell makinga protein. By the time you count up how many of the plasmids you initially inject versus how many are getting to the right place doing the right thing, it’s an infinitesimally small proportion of what you’ve injected,” Dr. Ulmer says. “Electroporation, alternatively, is a
brute force way of getting DNA past
one of the physical barriers and into
cells,” adds Dr. Ulmer.“It is conceivable
this could be accomplished in humans.”
Adds NCI’s Dr. George Pavlakis: “I
have stated in my public seminars that
for us, electroporation is right now the
gold standard for DNA vaccine delivery, giving us the best result in terms of immunogenicity of DNA vaccines.
When this technology matures, it will
be one of the most competitive for
DNA vaccine delivery.”
Novartis has been on the sideline to see how EP translates into humans, I think they have that answered now.
Dr. Philip D. Greenberg one of Inovio's top scientist ... Published on Jul 26, 2013
Cancer Research Institute's Breakthroughs in Cancer Immunotherapy Webinar Series are offered free to the public and feature informative updates from leaders in cancer immunotherapy, followed by a moderated Q&A. On June 25, 2013, Dr. Philip D. Greenberg, a professor of Medicine (Oncology) and Immunology, in the Fred Hutchinson Cancer Research Center at the University of Washington, described his groundbreaking research on the immunobiology of host T cell responses to infectious viruses and transformed (cancerous or pre-cancerous) cells. Among his notable contributions to the field is his ongoing work to create effective immunotherapies using the adoptive transfer approach, in which populations of T cells that selectively recognize targets found in cancer cells are expanded and reintroduced to the cancer patient. This approach has seen recent successes and is one of the ways scientists hope to unleash the body's natural immune defenses against cancer.
watch the video
link-
There is a conference coming up in the beginning of 2014 called
6th Immunotherapeutics & Immunomonitoring
Jan 29, 2014 to Jan 31, 2014
San Diego, CA, USA
3:30-New Technologies for Improved Vaccines Against Infectious Diseases and Cancer
Jeffrey Ulmer
Global Head, External Research
Novartis
Vaccines are without a doubt the most successful of mankind’s medical interventions. However, despite more than two centuries of effective use of vaccines, many substantial challenges remain. These include: 1) improvement of existing but suboptimal vaccines (e.g., tuberculosis, influenza), 2) discovery and development of new vaccines against targets to address large unmet medical needs (e.g., HIV, malaria, cancer), and 3) rapidly responding to new pathogens (e.g., newly emerging microbes, bioweapons). Recent advancements have demonstrated proof of concept for active immunization in the treatment of cancers. Taking full advantage will require the application of new technologies and paradigms in the areas of tumor antigen identification and optimization, novel potent and safe adjuvants, and enhanced vaccine delivery systems.
3:55-Kate Broderick
Director, Research & Development
Inovio
Kate Broderick is an employee of Inovio, is the one that has been featured in the inovio and novartis recent studies....she's is sharing under the same session as Novartis..note that those are the only two compaines presenting under the title -New Technologies for Improved Vaccines Against Infectious Diseases and Cancer-
yes this conference is early next year, the partnership should be inked before then(just my assumption)here is a link to the conference I am referencing
http://www.gtcbio.com/conference/immunotherapeutics-and-immunomonitoring-agenda#day2
also a Upenn and Novartis relationship has been brewing since last year..I guarantee that Inovio fits in this relationship somewhere we will see soon if my assumptions were right though this is just my opinion, but if you check out the patents coming forward this year by Novartis scientist and the patents by INO you will understand why I believe this partnership will happen(look further into that) on your own time and you will find the connections.
August 6, 2012
Novartis will contribute $20-million to build a center for cancer studies at the University of Pennsylvania, where researchers will try to bring new treatments to market, according to The New York Times. The partnership aims to build on the results of an experimental treatment that manipulates a patient’s immune system to attack cancer cells. Under the terms of an agreement, Penn will grant the Switzerland-based company exclusive rights to the treatment technologies, and the university will receive royalties as well as payments for reaching certain milestones.
Not everything Upenn does has to do with Inovio but when you check out all there work being done you'll see that electroporation is the method all these T-cell treatments are being delivered with(do your DD on that)